Balyasny Asset Management
CATX icon

Balyasny Asset Management’s Perspective Therapeutics CATX Stock Holding History

Balyasny Asset Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
3,320,224
+325,764
+11% +$1.23M 0.01% 1000
2026
Q1 		$12.5M Buy
+2,994,460
New +$12.7M 0.02% 932
2025
Q1 		– Sell
-130,914
Closed -$418K – 2831
2024
Q4 		$418K Buy
+130,914
New +$1.07M ﹤0.01% 2257
2024
Q2 		– Sell
-11,172
Closed -$133K – 2616
2024
Q1 		$133K Buy
+11,172
New +$95.3K ﹤0.01% 2474

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Balyasny Asset Management's CATX Position: Q2 2026 in Review

Balyasny Asset Management increased its Perspective Therapeutics (CATX) stake by 11% in Q2 2026, buying an estimated $1.23M and bringing the position to 3,320,224 shares worth $11.3M. The position accounts for 0.01% of the portfolio, ranked #1000.

Balyasny Asset Management first reported a position in CATX in Q1 2024 and has held it in 4 quarters since. The position peaked at $12.5M in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Balyasny Asset Management held 3,320,224 shares of Perspective Therapeutics worth $11.3M as of Q2 2026.
  • Balyasny Asset Management bought 325,764 Perspective Therapeutics shares in Q2 2026, an estimated $1.23M.
  • Perspective Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1000 holding.
  • Balyasny Asset Management first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Balyasny Asset Management's Perspective Therapeutics position peaked at $12.5M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.